Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.
10.1097/CM9.0000000000001888
- Author:
Rafael S RIOS
1
;
Kenneth I ZHENG
1
;
Ming-Hua ZHENG
1
Author Information
1. NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
- Publication Type:Review
- MeSH:
Carcinoma, Hepatocellular/etiology*;
Humans;
Liver Cirrhosis;
Liver Neoplasms/etiology*;
Non-alcoholic Fatty Liver Disease;
Obesity
- From:
Chinese Medical Journal
2021;134(24):2911-2921
- CountryChina
- Language:English
-
Abstract:
The emergence of non-alcoholic fatty liver disease (NAFLD) as the leading chronic liver disease worldwide raises some concerns. In particular, NAFLD is closely tied to sedentary lifestyle habits and associated with other metabolic diseases, such as obesity and diabetes. At the end of the disease spectrum, non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), representing a serious health problem to modern society. Recently, an increasing number of HCC cases originating from this progressive disease spectrum have been identified, with different levels of severity and complications. Updating the current guidelines by placing a bigger focus on this emerging cause and highlighting some of its unique features is necessary. Since, the drivers of the disease are complex and multifactorial, in order to improve future outcomes, having a better understanding of NASH progression into HCC may be helpful. The risks that can promote disease progression and currently available management strategies employed to monitor and treat NASH-related HCC make up the bulk of this review.
